U
MRTX

UBS’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

UBS’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$174K Sell
9,950
-4,662
-32% -$87K ﹤0.01% 5335
2014
Q2 		$292K Sell
14,612
-21,771
-60% -$420K ﹤0.01% 4776
2014
Q1 		$694K Buy
36,383
+27,875
+328% +$579K ﹤0.01% 3898
2013
Q4 		$142K Sell
8,508
-655
-7% -$11.2K ﹤0.01% 5671
2013
Q3 		$139K Buy
+9,163
New +$90.1K ﹤0.01% 5636

Other funds holding MRTX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

UBS's MRTX Position: Q3 2014 in Review

UBS reduced its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 32% in Q3 2014, selling an estimated $87K and leaving 9,950 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #5335.

UBS first reported a position in MRTX in Q3 2013 and has held it in 5 quarters since. The position peaked at $694K in Q1 2014. 43 funds tracked by Wall St. Rank hold MRTX as of Q3 2014.

  • UBS held 9,950 shares of Mirati Therapeutics, Inc. Common Stock worth $174K as of Q3 2014.
  • UBS sold 4,662 Mirati Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $87K.
  • Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5335 holding.
  • UBS first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2013 and has held it in 5 quarters since.
  • UBS's Mirati Therapeutics, Inc. Common Stock position peaked at $694K in Q1 2014.
  • 43 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.